{"id":31592,"date":"2025-04-11T13:54:02","date_gmt":"2025-04-11T05:54:02","guid":{"rendered":"https:\/\/flcube.com\/?p=31592"},"modified":"2025-04-11T13:54:03","modified_gmt":"2025-04-11T05:54:03","slug":"bayers-vitrakvi-fully-approved-by-fda-for-ntrk-fusion-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31592","title":{"rendered":"Bayer&#8217;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors"},"content":{"rendered":"\n<p>Germany-based Bayer (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The approval is based on comprehensive results from three multi-center, open-label, single-arm clinical studies: LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431). These studies included 339 pediatric and adult patients with unresectable or metastatic solid tumors with an NTRK gene fusion. Key findings include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overall Response Rate (ORR):<\/strong> 60% (95% CI: 55%-65%)<\/li>\n\n\n\n<li><strong>Complete Response (CR) Rate:<\/strong> 24%<\/li>\n\n\n\n<li><strong>Partial Response (PR) Rate:<\/strong> 36%<\/li>\n\n\n\n<li><strong>Median Duration of Response (DOR):<\/strong> 43.3 months<\/li>\n<\/ul>\n\n\n\n<p><strong>Drug Mechanism<\/strong><br>Vitrakvi is a TRK inhibitor designed to target tumors with NTRK gene fusions. By inhibiting the TRK signaling pathway, the drug effectively disrupts the growth and survival of cancer cells. This mechanism of action makes Vitrakvi a targeted therapy for a broad range of solid tumors driven by NTRK alterations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,15],"class_list":["post-31592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer&#039;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31592\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31592\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-11T05:54:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-11T05:54:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer&#8217;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors\",\"datePublished\":\"2025-04-11T05:54:02+00:00\",\"dateModified\":\"2025-04-11T05:54:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1104-png.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31592#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31592\",\"name\":\"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1104-png.webp\",\"datePublished\":\"2025-04-11T05:54:02+00:00\",\"dateModified\":\"2025-04-11T05:54:03+00:00\",\"description\":\"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31592\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1104-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1104-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31592#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer&#8217;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31592","og_locale":"en_US","og_type":"article","og_title":"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors","og_description":"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.","og_url":"https:\/\/flcube.com\/?p=31592","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-11T05:54:02+00:00","article_modified_time":"2025-04-11T05:54:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31592#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31592"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer&#8217;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors","datePublished":"2025-04-11T05:54:02+00:00","dateModified":"2025-04-11T05:54:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31592"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","keywords":["Bayer","ETR: BAYN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31592#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31592","url":"https:\/\/flcube.com\/?p=31592","name":"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31592#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","datePublished":"2025-04-11T05:54:02+00:00","dateModified":"2025-04-11T05:54:03+00:00","description":"Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food and Drug Administration (FDA) for its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib). The drug is now approved for adult and pediatric patients with solid tumors harboring an NTRK gene fusion without a known acquired resistance mutation, which are metastatic or where surgical resection is likely to result in severe morbidity, and for whom there are no satisfactory alternative treatments or that have progressed following treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31592#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31592"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31592#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","width":1080,"height":608,"caption":"Bayer's Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31592#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer&#8217;s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1104-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31592"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31592\/revisions"}],"predecessor-version":[{"id":31596,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31592\/revisions\/31596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31595"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}